STOCK TITAN

Aim Immunotech - AIM STOCK NEWS

Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.

Overview of AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company engaged in the research and development of advanced therapeutics to address critical challenges in cancer therapy, immune-deficiency disorders, and viral diseases. With a robust focus on clinical research and strategic development, the company leverages cutting-edge biotechnology to transform the landscape of therapeutic solutions. Key industry terms such as immuno-pharma, therapeutics, and clinical trials are embedded in its research activities, underlining its commitment to modern, science-driven treatments.

Core Business Areas

AIM ImmunoTech concentrates on two major product categories. The first is an injectable formulation of naturally derived alpha interferon, designed to address specific sexually transmitted diseases, such as the treatment of certain genital warts. The second flagship therapeutic, Ampligen, is a macromolecular ribonucleic acid molecule deployed in clinical trials targeting conditions like chronic fatigue syndrome as well as multiple cancer types including renal cell carcinoma, malignant melanoma, and advanced recurrent ovarian cancer. The company’s interest in Ampligen also extends to exploring its potential as an adjuvant therapy in infectious diseases, as evidenced by its research in combination with interferon and other immune modulators.

Research, Development, and Collaborations

At the heart of AIM ImmunoTech's operations lies a rigorous commitment to clinical innovation. The company is actively involved in multi-phase clinical investigations for various conditions, including studies on refractory cancers and assessments of its drugs as vaccine adjuvants. Collaborations with esteemed institutions, such as research agreements with international partners including the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., further underscore its strategic approach to expanding the therapeutic applications of its products. These partnerships illustrate a balanced research model that addresses both immunotherapy and anti-viral research, exemplifying the company’s proficiency in navigating complex biomedical landscapes.

Operational Excellence and Strategic Positioning

AIM ImmunoTech has established itself within a competitive biopharmaceutical sector by consistently pursuing clinical research excellence and targeting unmet medical needs. Its therapeutic portfolio is designed to harness the body’s natural immune response while providing innovative clinical solutions across multiple health conditions. The company’s research efforts are supported by rigorous clinical trials and detailed investigations which focus on enhancing drug efficacy and safety. With its diversified pipeline, the company demonstrates a strategic approach to mitigating risks associated with clinical development and capitalizing on opportunities within the evolving landscape of cancer and viral treatment modalities.

Market Significance and Competitive Landscape

The company occupies a unique niche within the immuno-pharma market. Unlike larger, more diversified pharmaceutical companies, AIM ImmunoTech’s focused approach on specialized therapeutics positions it as a significant contributor to niche therapeutic areas that remain underexplored by mainstream industry players. Its collaborative research strategy and emphasis on innovative therapies such as Ampligen have helped bolster its standing within a highly competitive market. AIM’s approach combines the rigors of clinical research with strategic partnerships, ensuring that its products are developed with precision and scientific integrity.

Scientific Rigor and Clinical Expertise

Clinical investigations conducted by AIM ImmunoTech are characterized by meticulous study design and scientific scrutiny. The company has been involved in numerous phase 1, 2, and exploratory trials that seek to validate the efficacy of its compounds across various challenging conditions. By integrating detailed clinical protocols and a commitment to evidence-based research, AIM ImmunoTech showcases a depth of expertise and a nuanced understanding of the interrelationships between diverse medical conditions such as cancer, chronic fatigue syndrome, and viral infections.

Conclusion

Overall, AIM ImmunoTech Inc. stands as a model of focused innovation within the immuno-pharma sector. Its sustained commitment to advancing clinical research, developing groundbreaking therapeutics, and fostering strategic international collaborations provides a comprehensive insight into its business operations. For those seeking an in-depth understanding of a company dedicated to transforming therapeutic paradigms in oncology and virology, AIM ImmunoTech represents a case study in applied scientific expertise and clinical diligence.

Rhea-AI Summary

AIM ImmunoTech Inc. announced positive results in testing Ampligen and Imfinzi in late-stage pancreatic cancer treatment. The combination was well-tolerated with no severe adverse events. The next safety cohort will start escalated dosing soon. Subjects will be monitored for response for up to 48 weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
-
Rhea-AI Summary
AIM ImmunoTech announces the release of the next CEO Corner segment featuring an overview of Metastatic Pancreatic Cancer and the ongoing Phase 1b/2 clinical trial combining Ampligen® with Imfinzi® for the treatment of late-stage pancreatic cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
none
-
Rhea-AI Summary
AIM ImmunoTech announces the release of the next CEO Corner segment featuring an overview of Locally Advanced Pancreatic Adenocarcinoma and the unmet need by Thomas Equels, the Chief Executive Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
AIM ImmunoTech appoints Dr. Charles Lapp as Consulting Medical Officer for ME/CFS and Long COVID Programs, aiming to develop Ampligen as a potential treatment. Dr. Lapp's expertise and dedication to FDA approval are highlighted, with CEO Equels praising his contribution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.29%
Tags
covid-19
-
Rhea-AI Summary
AIM ImmunoTech Inc. announces the publication of the CEO Corner segment discussing the potential synergistic effect of combining Ampligen with Keytruda in the treatment of recurrent ovarian cancer, indicating promising results for the therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.93%
Tags
none
-
Rhea-AI Summary
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased anti-tumor immunity, indicating potential for broader application across various cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
Rhea-AI Summary
AIM ImmunoTech Inc. reports financial results for 2023, highlighting positive data and milestones achieved in various clinical studies. The company aims to create stockholder value through operational, clinical, and regulatory initiatives. Key highlights include positive findings in treating pancreatic cancer and Post-COVID fatigue, as well as bolstering intellectual property. Financially, the company reported $13.1 million in cash and investments, with increased R&D and administrative expenses compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.16%
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. will present at the MedInvest Biotech & Pharma Investor Conference on April 3rd, 2024. Thomas K. Equels, CEO, will discuss company updates and meet with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
conferences
-
Rhea-AI Summary
AIM ImmunoTech Inc. to discuss Q4/FY2023 results in a conference call on April 2, 2024, led by CEO Thomas K. Equels and Scientific Officer Christopher McAleer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
AIM ImmunoTech Inc. announces positive data analysis from a study on Ampligen in treating advanced pancreatic cancer. The study shows immune-stimulatory properties of TLR-3 activation, enhancing anti-tumor immunity through dendritic cell-mediated T cell responses. Ampligen treatment correlates with improved clinical outcomes and decreased expression of immune checkpoints. The company aims to expand Ampligen's application to various solid tumor types, with ongoing clinical trials to evaluate its effectiveness in pancreatic cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Aim Immunotech (AIM)?

The current stock price of Aim Immunotech (AIM) is $0.0949 as of April 4, 2025.

What is the market cap of Aim Immunotech (AIM)?

The market cap of Aim Immunotech (AIM) is approximately 5.1M.

What is the core focus of AIM ImmunoTech Inc.?

AIM ImmunoTech Inc. is primarily focused on the research and development of novel therapeutics to treat various forms of cancer, immune-deficiency disorders, and viral diseases.

What are the main therapeutic products developed by AIM ImmunoTech?

The company develops products such as an injectable formulation of natural alpha interferon for certain STDs and Ampligen, a macromolecular RNA-based molecule investigated for cancer, chronic fatigue syndrome, and viral infections.

How does AIM ImmunoTech position itself within the biopharmaceutical industry?

The company positions itself by focusing on specialized therapeutic areas and leveraging robust clinical research and collaborations with renowned international partners to validate its compounds.

What is the significance of Ampligen in AIM ImmunoTech’s product portfolio?

Ampligen plays a key role as a versatile therapeutic candidate that is being evaluated for its efficacy in treating a range of conditions including various cancers, chronic fatigue syndrome, and its potential as a vaccine adjuvant.

How does the company approach clinical research and product development?

AIM ImmunoTech emphasizes rigorous clinical trial methodologies, strategic partnerships, and detailed research protocols to ensure that its therapeutic candidates meet high standards of safety and efficacy.

What distinguishes AIM ImmunoTech from other companies in the immuno-pharma sector?

Its focused approach on niche therapeutic areas, commitment to innovative clinical research, and strategic international collaborations allow AIM ImmunoTech to address unmet medical needs and differentiate itself within a competitive market.
Aim Immunotech

NYSE:AIM

AIM Rankings

AIM Stock Data

5.09M
67.24M
10.11%
12.54%
4.78%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
OCALA